Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company

行业资深人士将领导商业扩张，推动公司的创新和增长。

SALT LAKE CITY

盐湖城

,

，

May 8, 2025

2025年5月8日

/PRNewswire/ --

/美通社/ --

Sera Prognostics Inc.

塞拉预后公司

, The Pregnancy Company

，怀孕公司

®

®

(Nasdaq:

纳斯达克：

SERA

SERA

), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of

），专注于通过向医生和患者提供创新的妊娠生物标志物信息来改善母婴健康，今天宣布任命

Lee Anderson

李·安德森

as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.

作为首席商务官。安德森先生在销售、市场营销、客户服务、战略客户和培训方面拥有超过30年的跨职能领导经验，他在推动医疗保健领域的业务增长和提升销售策略方面有着良好的记录。

Lee Anderson

李·安德森

'Lee is a highly accomplished leader with commercial expertise in fostering innovation, supporting continuous optimization and driving sales and offers a history of strong performance within the healthcare and diagnostics space,' said Zhenya Lindgardt, President and CEO of Sera Prognostics. 'With Sera now in the commercial phase following the strong results of our pivotal PRIME study, Lee will play a critical role in expanding adoption and sales of our PreTRM Test and we enthusiastically welcome Lee to our leadership team.'.

“李是一位极具成就的领导者，在推动创新、支持持续优化和促进销售方面具有商业专长，并在医疗保健和诊断领域有着卓越的表现历史，”Sera Prognostics公司总裁兼首席执行官珍娅·林加德表示。“随着Sera在我们关键的PRIME研究取得强劲结果后进入商业化阶段，李将在扩大我们的PreTRM测试的采用率和销售方面发挥关键作用，我们热烈欢迎李加入我们的领导团队。”

Mr. Anderson comes to Sera with a robust track record in leadership roles within the biotechnology and diagnostics sector, primarily highlighted by his transformative tenure at Genomic Health and Exact Sciences. At Genomic Health, which was later acquired by Exact Sciences, he escalated through various levels of increasing responsibility, finally spearheading US Oncology Sales and Global Customer Service as Vice President.

安德森先生来到塞拉公司，带来了在生物技术和诊断行业领导岗位上的丰富履历，尤其是在Genomic Health和Exact Sciences的变革性任职经历。在后来被Exact Sciences收购的Genomic Health期间，他历任多个责任不断增加的职位，最终作为副总裁领导了美国肿瘤学销售和全球客户服务。

Under his stewardship, he propelled the company into a leading product distributor in diagnostics, celebrating an impressive streak of nine consecutive years of revenue growth. His strategic acumen continued to thrive post-acquisition, where he excelled as the General Manager of Precision Oncology at Exact Sciences.

在他的领导下，他使公司成为诊断领域的领先产品分销商，实现了连续九年收入增长的惊人记录。他的战略才能在收购后继续发扬光大，在Exact Sciences担任精准肿瘤学总经理期间表现出色。

Here, he was instrumental in driving nationwide sales growth and spearheading the launch of innovative new products..

在这里，他在推动全国销售增长和率先推出创新新产品方面发挥了重要作用。

Following his impactful tenure in these companies, Mr. Anderson held the role of Chief Commercial Officer at Biofidelity Inc. There, he leveraged his extensive experience to enhance their commercial strategy and significantly advance their market presence. Mr. Anderson holds a Bachelor of Science degree in Biology/.

在这些公司任职后，安德森先生在Biofidelity Inc.担任首席商务官。在那里，他利用其丰富的经验改进了公司的商业战略，并极大地提升了市场影响力。安德森先生拥有生物学学士学位。

Pre Medicine

医学预科

with a Minor in Chemistry from

辅修化学来自

Florida State University

佛罗里达州立大学

, Tallahassee.

，塔拉哈西。

'I have been fortunate throughout my career to work for companies whose products were truly life changing,' said Mr. Anderson. 'Sera Prognostics is one of those companies. Together, this team will transform women's health care and positively impact the lives of mothers and their babies.'

“在我的职业生涯中，我很幸运能为那些产品真正改变生命的企业工作，”安德森先生说。“Sera Prognostics 就是这样一家公司。这个团队将共同变革女性医疗保健，并对母亲及其婴儿的生活产生积极影响。”

About Sera Prognostics, Inc.

关于Sera Prognostics公司

Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery.

Sera Prognostics是一家领先的健康诊断公司，致力于通过精准的孕期护理改善妇女和婴儿的生活。Sera的使命是提供早期、关键的妊娠信息，以改善母亲和新生儿的健康状况，从而降低医疗保健服务的成本。

Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera's precision medicine PreTRM.

Sera拥有一个强大的创新诊断测试管道，专注于早产风险和其他妊娠并发症的早期预测。Sera的精准医疗PreTRM。

®

®

Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in

向医生报告妊娠期间个体化的自发性早产风险，以便对高风险孕妇进行更早期的主动干预。Sera Prognostics 总部位于

Salt Lake City, Utah

犹他州盐湖城

.

。

About Preterm Birth

关于早产

Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns. The 2024 March of Dimes Report Card shows that, for the last six consecutive years, more than one in ten infants is born prematurely in

早产被定义为在怀孕37周之前出生，是新生儿疾病和死亡的主要原因。2024年美国“生命行军”基金会的报告显示，在过去连续六年中，每十个婴儿中就有一个以上是早产的。

the United States

美国

. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children.

早产与主要长期医疗并发症的风险显著增加相关，这些并发症包括学习障碍、脑瘫、慢性呼吸系统疾病、智力障碍、癫痫发作以及视力和听力丧失，并且会在受影响儿童的一生中产生巨大的费用。

The annual health care costs to manage short- and long-term complications of prematurity in .

管理早产短期和长期并发症的年度医疗费用。

the United States

美国

were estimated to be approximately

估计约为

$25 billion

250亿美元

for 2016.

对于2016年。

About the PreTRM

关于PreTRM

®

®

Test

测试

The PreTRM

PreTRM

®

®

Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM

Test 是唯一经过广泛验证、商业可用的基于血液的生物标志物检测，可为无症状单胎妊娠的自发性早产提供早期、准确且个体化的风险预测。PreTRM

®

®

Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM

测试测量并分析血液中的蛋白质，这些蛋白质对早产具有高度预测性。PreTRM

®

®

Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM

测试允许医生在怀孕的第18至20周期间识别哪些女性面临更高的早产及其并发症风险，从而根据每位女性的个体风险做出更明智、个性化的临床决策。PreTRM

®

®

Test is ordered by a medical professional.

测试由医疗专业人员安排。

Sera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other countries.

Sera、Sera Prognostics、Sera Prognostics 标志、The Pregnancy Company 和 PreTRM 是 Sera Prognostics, Inc. 在美国和/或其他国家的商标或注册商标。

Safe Harbor Statement

安全港声明

This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to expanding adoption and sales of our PreTRM test; long-term growth opportunities; the Company's ability to transform women's health care and positively impact the lives of mothers and their babies; ramping-up the Company's commercial strategy and developing market opportunities; and the Company's strategic directives under the caption 'About Sera Prognostics, Inc.' These 'forward-looking statements' are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的“前瞻性声明”，包括与扩大我们PreTRM测试的采用和销售相关的声明；长期增长机会；公司转变女性医疗保健并积极影响母亲及其婴儿生活的能力；推进公司的商业战略和开发市场机会；以及标题为“关于Sera Prognostics, Inc.”下公司的战略方针。这些“前瞻性声明”基于管理层对未来事件的当前预期，并受到许多可能导致实际结果与前瞻性声明中明示或暗示的结果有重大不利差异的风险和不确定性的影响。

These risks and uncertainties include, but are not limited to: net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM Test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM Test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading 'Risk Factors' contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

这些风险和不确定性包括但不限于：净亏损、现金生成以及可能需要筹集更多资本；PreTRM测试的收入目前占公司总收入的绝大部分；PreTRM测试需要广泛的科学和市场认可；客户集中度较高；我们推出新产品的能力；潜在竞争；我们的专有生物样本库；关键供应商；对总体可触达市场机会的估算及市场增长预测；潜在的第三方支付方覆盖和报销；适用于PreTRM测试的新报销方法，包括新的CPT代码及其支付率；FDA对实验室开发测试的监管变化；保护我们测试和市场地位的知识产权；以及其他在我们年度报告10-K表格和季度报告10-Q表格中“风险因素”标题下讨论的因素。

SOURCE Sera Prognostics, Inc.

来源：Sera Prognostics, Inc.

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用